Recent perspectives of pediatric β-thalassemia

An, Qi; Xu, Shi‐Hai

doi:10.23736/s2724-5276.18.04872-7

Cited by 1 publication

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transfusion of red blood cells (RBCs), either prophylactic or therapeutic, is the mainstay of treatment for thalassemia. 1,2 Transfusiondependent thalassemia patients require life-long regular transfusion for survival while nontransfusion-dependent patients receive transfusion only during exacerbation of anemia. 3,4 Frequent transfusions, however, are not without risk and complications form transfusion constitute major causes of morbidity in transfusion-dependent patients.…”

Section: Introductionmentioning

confidence: 99%

“…Thalassemia syndromes are heterogenous group of disorders that include a wide range of genetic disturbances in α and β genes. Transfusion of red blood cells (RBCs), either prophylactic or therapeutic, is the mainstay of treatment for thalassemia 1,2 . Transfusion‐dependent thalassemia patients require life‐long regular transfusion for survival while nontransfusion‐dependent patients receive transfusion only during exacerbation of anemia 3,4 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of pediatric transfusion‐dependent thalassemia patients in a large academic center

Zarrabian,

Hanna

2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundTransfusion‐dependent thalassemia patients are at high risk of transfusion‐related complications. Yet, there is scanty data on the frequency of transfusion reactions, particularity alloimmunization among pediatric transfusion‐dependent thalassemia patients. In addition, there is no consensus on the prophylactic antigen matching for prevention of alloimmunization or the extent of antigen matching for alloimmunized thalassemia patients.MethodsWe conducted a retrospective study to assess the frequency and specificity of alloimmunization among pediatric transfusion‐dependent thalassemia patients receiving ABO, RhD, and K‐matched red blood cell units. In addition, we studied the association between patients' characteristics and alloimmunization. The clinical and transfusion records of transfusion‐dependent thalassemia patients followed up at our institution between July 2018 and June 2022 were reviewed.ResultsNinety‐two transfusion‐dependent thalassemia patients having mean age of 13.37 years (SD, 5.56) were included in our study. Eight patients (9%) had developed clinically significant alloantibodies; six patients (6%) developed alloantibody against E antigen while two patients (2%) developed more than one alloantibody. Of alloimmunized patients, five patients had received transfusion outside Canada. Patients' sex, age, having a genotype variant, total number, and duration of transfusion received were not associated with the risk of alloimmunization. The transfusion‐recipient's diagnosis of β‐thalassemia, having developed autoantibody, and history of receiving transfusion outside Canada were associated with alloimmunization.ConclusionBlood matching for ABO, RhD, and K antigens resulted in, although not eliminated, lower frequency of alloimmunization than that previously reported among pediatric thalassemia patients. Extending matching to include Rh antigens could further reduce the rate of alloimmunization.

show abstract